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Objectives
The objective of this study was to investigate the short-
term effect of highly active antiretroviral therapy on the
CD4 lymphocyte count of HIV-infected Nigerians.
Setting
This study was carried out at the Haematology Depart-
ment of the University of Port Harcourt Teaching Hospital
a 500 bed tertiary hospital and one of the designated
antiretroviral therapy pilot centres.
Methods
A case control study of 70 HIV-infected subjects placed on
highly active antiretroviral therapy. Thirty HIV-infected
yet to start therapy due to unaffordability were observed
as controls. CD4 lymphocyte count was determined at
baseline for subjects and controls. Subjects were placed on
HAART for 12 weeks while controls that were yet to start
therapy were monitored as controls. CD4 lymphocyte
count was repeated after 12 weeks and the differences
compared statistically.
Results
We observed that subjects and control patients did not dif-
fer significantly in their CD4 lymphocyte count at base-
line (p > 0.05), but after 12 weeks HAART in subjects,
there was a mean increase in CD4 count of (39 cells/μl) in
subjects, while untreated controls showed a mean decline
of (12 cells/μl) p < 0.05. There was a statistically signifi-
cant variation in the therapy dependent increases in CD4
count of HAART treated subjects based on pre-therapeutic
baseline CD4 count (χ2 = 180.39, p < 0.05). The HAART
dependent increase in CD4 counts was higher in younger
subjects 19-28 years (31 cells/μl) compared to older sub-
jects 49-58 years (21 cells/μl) (p = 0.01). Similarly CD4
response was found higher in females compared to males
(p = 0.01).
Conclusion
This study indicates the importance of accessing the CD4
lymphocyte count of HIV infected patients before the ini-
tiation of HAART, its use as a prognostic maker in predict-
ing the initial response to HAART and in determining the
optimal time to initiate therapy.
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